Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01564602
Other study ID # VGH2011-03-011IA
Secondary ID
Status Recruiting
Phase N/A
First received February 20, 2012
Last updated March 28, 2012
Start date January 2011
Est. completion date December 2014

Study information

Verified date March 2012
Source Taipei Veterans General Hospital, Taiwan
Contact n/a
Is FDA regulated No
Health authority Taiwan: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The main objective of this trial is to assess the efficacy and safety of single port-access laparoscopic-assisted vaginal hysterectomy. The operative time, weight of the uterus, blood loss and hospital stay will be record, respectively. The pain score is based on the visual analogue scale in which patients record the intensity of their pain 12, 24, and 48 hours after surgery.


Description:

Single port laparoscopy is an attempt to further enhance the cosmetic benefits of minimally invasive surgery while minimizing the potential morbidity associated with multiple incisions. Preliminary advances in LESS as applied to urologic and gastrointestinal surgery demonstrate that the techniques are feasible provided that both optimal surgical technical expertise with advanced skills and optimal instrumentation are available. Recently, Lee et al. performed the multiple channel single port-access laparoscopic-assisted vaginal hysterectomy (SPA-LAVH) in 24 patient. All cases but 3 were performed exclusively through a single port. The median operative time, weight of the uterus, and estimated blood loss were 119 minutes (range 90 to 255 minutes), 347 g (range 225 to 732 g), and 400 mL (range 100 to 1000 mL), respectively. The median hospital stay (postoperative day) was 3 days (range 3 to 7). Although there are a limited number of studies demonstrating the feasibility of single-port access laparoscopic-assisted vaginal hysterectomy (LAVH), single-port surgery is "new-old" (i.e., a revisited and unstandardized technique) because the major disadvantage of limited movement caused by collisions of the laparoscopic instruments has been mitigated by the development of multi-channel approaches. Therefore, the investigators used a 2-channel single-port system, which was different from the previously published 3-channel single-port technique11,12 to reduce collisions and aid the assistant in controlling the scope without interfering with the surgeon's instruments. To our knowledge, there are no randomize control trial to evaluate of 2-channel or multiple channel single port laparoscopic surgery in gynecologic disorders. The purpose of this study was to assess the feasibility of 2-channel and multiple-channel single port laparoscopy in the treatment of benign uterine disease.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date December 2014
Est. primary completion date January 2014
Accepts healthy volunteers No
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria:

- Patients receive laparoscopic-assisted vaginal hysterectomy (LAVH)

- American Society of Anesthesiologists (ASA) physical status of patient: classification I-II

Exclusion Criteria:

- The procedure will be required to conversion to laparotomy.

- Any cardio-vascular diseases.

- Malignant disease

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
comparison multiple channel port laparoscopic surgery
to compare 2-channel single port and multiple channel port laparoscopic surgery

Locations

Country Name City State
Taiwan Taipei Veterans General Hospital Taipei

Sponsors (1)

Lead Sponsor Collaborator
Taipei Veterans General Hospital, Taiwan

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary The operative time We will follow the patients until one month after the surgery. The primary outcome measure of this trial is the effect and safety of single port-access laparoscopic-assisted vaginal hysterectomy. We will follow the patients until one month after the surgery. Yes
Secondary weight of the uterus one month Yes
Secondary blood loss one month Yes
Secondary hospital length of stay one month Yes
Secondary morbidity one month No
See also
  Status Clinical Trial Phase
Completed NCT04665414 - Diagnosis of Adenomyosis Using Ultrasound, Elastography and MRI
Recruiting NCT04209127 - Comparing Efficacy of Microwave vs Embolization Treatment for Adenomyosis N/A
Completed NCT05751876 - Dienogest in Perimenopausal Women With Adenomyosis
Recruiting NCT01048931 - Single-port Access Laparoscopic-assisted Vaginal Hysterectomy Phase 3
Active, not recruiting NCT06223464 - Evaluation of the Relationship Between Adenomyosis and Elastographic Properties of the Cervix
Completed NCT05419414 - The Use of Shear Wave Elastography, Transvaginal Ultrasound and Pelvic MRI in the Diagnosis of Adenomyosis N/A
Recruiting NCT05152667 - Ambispective Study to Assess the Effect of Pretreatment With a Levonorgestrel-Releasing Intrauterine System Versus Oral Progestin
Not yet recruiting NCT03654144 - Role of Dienogest in the Treatment of Patient With Symptomatic Adenomyosis Phase 4
Completed NCT02192606 - Does 3D Laparoscopy Improve Vaginal Cuff Suture Time? N/A
Completed NCT01992718 - What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography Early Phase 1
Recruiting NCT02495311 - The Association Between Adenomyosis/Uterine Myoma and Lower Urinary Tract Symptoms
Recruiting NCT03742843 - A Multi-omics Study of Adenomyosis
Recruiting NCT04481321 - Clinical and Molecular Study of Endometriosis and Adenomyosis
Recruiting NCT04894292 - The Effect of Adenomoyosis on Pregnancy Outcomes
Completed NCT03520439 - Evaluation of Therapeutic Effect and Safety of Mifepristone in the Treatment of Adenomyosis Phase 2/Phase 3
Recruiting NCT05937490 - Adenomyosis and ART Phase 4
Recruiting NCT06373822 - New Perspectives in Adenomyosis Pathogenesis With Epigenetic Analysis and miRNAs
Completed NCT01821001 - Vaginal Bromocriptine for Treatment of Adenomyosis Phase 1
Recruiting NCT04295109 - Comparison of the Effects of Fentanyl, Oxycodone, Butorphanol on Gastrointestinal Function N/A
Recruiting NCT04356664 - Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis Phase 2/Phase 3